Predictive Oncology subsidiary Helomics collaborates with UPMC
Predictive Oncology (Nasdaq: POAI) subsidiary Helomics, announced a joint collaborative agreement with UPMC to study the use of artificial intelligence to improve clinical decision making for ovarian cancer patients. July 18, 2019